2,65 $
8,16 % gestern
Nasdaq, 27. Oktober, 21:18 Uhr
ISIN
US12529R1077
Symbol
CCCC
Berichte

C4 Therapeutics Inc Aktie News

Neutral
GlobeNewsWire
12 Tage alt
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab
Neutral
GlobeNewsWire
27 Tage alt
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell ...
Neutral
Seeking Alpha
etwa ein Monat alt
C4 Therapeutics, Inc. - Special Call Company Participants Courtney Solberg - Senior Manager of Investor Relations Andrew Hirsch - CEO, President & Director Leonard M. J. Reyno - Chief Medical Officer Kendra Adams - CFO & Treasurer Conference Call Participants Sudan Loganathan - Stephens Inc., Research Division Binod Dhakal Bradley Canino - Guggenheim Securities, LLC, Research Division Etzer Dar...
Neutral
GlobeNewsWire
etwa ein Monat alt
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population
Positiv
The Motley Fool
etwa ein Monat alt
C4 Therapeutics (CCCC 33.84%) was not only one of the better-performing healthcare stocks on Monday, it was one of the big winners on the market, period. The company seemed to have a rocket strapped to its back, as its share price blasted more than 34% higher after an analyst upgraded his recommendation.
Neutral
GlobeNewsWire
etwa 2 Monate alt
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA).
Neutral
GlobeNewsWire
etwa 2 Monate alt
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) ...
Neutral
The Motley Fool
3 Monate alt
CCCC Revenue Drops 46%

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen